Showing results (41-50 of 60) with videos related to
Sort By:
Pageof 6
International Journal of Urology : Official Journal of the Japanese Urological Association|November 24, 2018
Incidence and predictive factors of hypoglycemia after pheochromocytoma resectionSaori Araki, Toshiki Kijima, Yuma Waseda, et al.International Journal of Urology : Official Journal of the Japanese Urological Association|July 16, 2024
Outcomes and prognostic factors in patients with synchronous and metachronous oligometastatic urothelial carcinoma with visceral metastasesSoichiro Yoshida, Yuya Maezawa, Kensaku Ishihara, et al.Journal of Clinical Medicine|November 11, 2020
A New Dyspnea Evaluation System Focusing on Patients' Perceptions of Dyspnea and Their Living Disabilities: The Linkage between COPD and FrailtyKeiji Oishi, Kazuto Matsunaga, Misa Harada, et al.Respiratory Investigation|July 10, 2021
Abundant TNF-LIGHT expression in the airways of patients with asthma with persistent airflow limitation: Association with nitrative and inflammatory profilesTsunahiko Hirano, Kazuto Matsunaga, Keiji Oishi, et al.European Urology Open Science|February 6, 2023
Defining Tumour Shape Irregularity for Preoperative Risk Stratification of Clinically Localised Renal Cell CarcinomaHajime Tanaka, Shohei Fukuda, Koichiro Kimura, et al.International Journal of Clinical Oncology|April 21, 2025
Prognostic factors and effect of existing predictive models in oligo-metastatic urothelial carcinoma (YUSHIMA study)Kenji Tanabe, Soichiro Yoshida, Tomoki Kimura, et al.International Journal of Clinical Oncology|June 4, 2024
Gustave Roussy Immune score as a prognostic biomarker in patients with platinum-refractory metastatic urothelial carcinoma treated with pembrolizumab: YUSHIMA studyKenji Tanabe, Shuichiro Kobayashi, Yuya Maezawa, et al.Cancer Medicine|September 5, 2020
Impact of radiotherapy to the primary tumor on the efficacy of pembrolizumab for patients with advanced urothelial cancer: A preliminary studyHiroshi Fukushima, Toshiki Kijima, Shohei Fukuda, et al.International Journal of Urology : Official Journal of the Japanese Urological Association|May 12, 2026
Performance of Prognostic Models in Patients With Metastatic Urothelial Carcinoma Treated With Enfortumab Vedotin After Platinum-Based Chemotherapy and Immune Checkpoint Inhibitors: YUSHIMA StudyHiroki Shimoda, Yuki Nakamura, Masaharu Inoue, et al.Japanese Journal of Clinical Oncology|March 16, 2026
Lymph node metastasis as a favorable prognostic factor in metastatic urothelial carcinoma with histological variants treated with pembrolizumab: a retrospective multicentric study (YUSHIMA study-04)Ichiro Yonese, Fumitaka Koga, Masahiro Toide, et al.Pageof 6